Fluvoxamine maleate + Placebo

Phase 3Completed
0 views this week 0 watching Active
Interest: 40/100
40
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Obsessive Compulsive Disorder

Conditions

Obsessive Compulsive Disorder

Trial Timeline

Aug 14, 2013 → Jul 1, 2016

About Fluvoxamine maleate + Placebo

Fluvoxamine maleate + Placebo is a phase 3 stage product being developed by AbbVie for Obsessive Compulsive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01933919. Target conditions include Obsessive Compulsive Disorder.

What happened to similar drugs?

5 of 9 similar drugs in Obsessive Compulsive Disorder were approved

Approved (5) Terminated (1) Active (3)

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01933919Phase 3Completed

Competing Products

17 competing products in Obsessive Compulsive Disorder

See all competitors
ProductCompanyStageHype Score
DuloxetineEli LillyApproved
43
quetiapine fumarate + SSRI/ClomipramineAstraZenecaPhase 3
40
QuetiapineAstraZenecaPhase 2
35
Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo)NovartisApproved
43
Bitopertin + Placebo + SSRIRochePhase 2
35
sertralinePfizerPre-clinical
26
pregabalin + PlaceboPfizerApproved
43
Sertraline + Levetiracetam + PlaceboUCBPhase 2/3
30
EscitalopramLundbeckApproved
36
Escitalopram + Placebo oral tabletLundbeckApproved
44
Valbenazine + PlaceboNeurocrine BiosciencesPhase 2
39
RG1068 (Synthetic Human Secretin)RepligenPhase 2
32
Troriluzole + PlaceboBiohavenPhase 3
34
Troriluzole + PlaceboBiohavenPhase 3
34
Troriluzole + PlaceboBiohavenPhase 2/3
32
Troriluzole (BHV-4157)BiohavenPhase 3
26
Nitrous Oxide + NitrogenBrain BiotechPhase 2
32